Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dare Bioscience, Inc.DARE · Entity 7799 | Director | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dare Bioscience, Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 26,066 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 26,066 · Balance 26,066 F1: Represents shares underlying restricted stock units ("RSU") granted to the reporting person in lieu of cash compensation for service on the issuer's board of directors and its committees. Each RSU represents a contingent right to receive one share when vested. The RSUs vests on January 4, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying restricted stock units ("RSU") granted to the reporting person in lieu of cash compensation for service on the issuer's board of directors and its committees. Each RSU represents a contingent right to receive one share when vested. The RSUs vests on January 4, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 20:21 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantCommon stock | 26,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001401914-26-000037 · wk-form4_1783023698.xml · nonDerivative · entry 1 Grossman Jessica D. · CIK 0001736781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,066 F1 · shares: Represents shares underlying restricted stock units ("RSU") granted to the reporting person in lieu of cash compensation for service on the issuer's board of directors and its committees. Each RSU represents a contingent right to receive one share when vested. The RSUs vests on January 4, 2027. Read SEC document |
| June 11, 2026 Filed Jun 11, 2026 20:47 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001736781-26-000002 · wk-form4_1781210876.xml · derivative · entry 1 Grossman Jessica D. · CIK 0001736781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common stock · 10,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| July 09, 2025 Filed Jul 10, 2025 20:05 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001401914-25-000037 · wk-form4_1752177920.xml · derivative · entry 1 Grossman Jessica D. · CIK 0001736781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Common stock · 4,500 shares Expires 2035-07-09 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:15 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001493152-24-023181 · ownership.xml · derivative · entry 1 Grossman Jessica D. · CIK 0001736781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common stock · 40,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 01:46 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001401914-23-000036 · wk-form4_1687398384.xml · derivative · entry 1 Grossman Jessica D. · CIK 0001736781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common stock · 40,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:30 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 38,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001401914-22-000062 · wf-form4_165610257799601.xml · derivative · entry 1 Grossman Jessica D. · CIK 0001736781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common stock · 38,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| June 24, 2021 Filed Jun 24, 2021 20:40 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001401914-21-000092 · wf-form4_162456719866945.xml · derivative · entry 1 Grossman Jessica D. · CIK 0001736781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common stock · 30,000 shares Expires 2031-06-24 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 00:55 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001401914-20-000094 · wf-form4_159321930436873.xml · derivative · entry 1 Grossman Jessica D. · CIK 0001736781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common stock · 22,500 shares Expires 2030-06-25 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 11:08 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001736781-19-000001 · wf-form4_156051051083771.xml · derivative · entry 1 Grossman Jessica D. · CIK 0001736781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common stock · 22,500 shares Expires 2029-06-13 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 21:42 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-18-042381 · doc4.xml · derivative · entry 1 Grossman Jessica D. · CIK 0001736781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-07-10 F1 · derivative.exercise_date: This option vests as to 1/3rd of the shares subject to this option on each of July 10, 2019, 2020 and 2021, subject to the reporting person's continued service to the issuer, and will become exercisable in full upon a change of control of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.